SOX2 mediates metabolic reprogramming of prostate cancer cells
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell L, Vellky J, Brown R, Conger K, Paner G, Wang H, Platz E, De Marzo A, Mu P, Coloff J, Szmulewitz R, Vander Griend D. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene 2022, 41: 1190-1202. PMID: 35067686, PMCID: PMC8858874, DOI: 10.1038/s41388-021-02157-x.Peer-Reviewed Original ResearchConceptsProstate cancer cellsSOX2 expressionCancer cellsTherapy resistanceMetastatic progressionMetabolic reprogrammingAssociated with multiple oncogenic pathwaysAndrogen-sensitive prostate cancer cellsGene targetingCastration-resistant prostate cancer cellsIncreased spare respiratory capacityChIP-seq analysisRNA-seq datasetsStem cell transcription factor Sox2Prostate cancer cell linesAnnotated tumor specimensSOX2 binding sitesPentose phosphate pathwayCRISPR-mediated deletionDecreased patient survivalSpare respiratory capacityQuantity of mitochondriaDeletion of Sox2Case-control cohortGene expression analysis